The global market for COVID-19 Drugs was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for COVID-19 Drugs, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of COVID-19 Drugs by region & country, by Type, and by Application.
The COVID-19 Drugs market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding COVID-19 Drugs.
麻豆原创 Segmentation
By Company
Sanofi
Novartis
Shanghai Zhongxisanwei
Teva
Zydus Cadila
Mylan
Apotex
Advanz Pharma
Sun Pharma
Kyung Poong
Ipca Laboratories
Hanlim Pharmaceutical
Bristol Laboratories
Bayer
Rising Pharmaceutical
Shanghai Pharma
Sichuan Sunny Hope
Guangzhou Baiyunshan Guanghua Pharmaceutical
CSPC Group
KPC Group
Jinghua Pharmaceutical Group
Zhongsheng Pharma
North China Pharmaceutical Group
Segment by Type:
Tablet
Injection
Segment by Application
Mild Symptom Patient
Critically Ill Patient
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of COVID-19 Drugs manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of COVID-19 Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of COVID-19 Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 麻豆原创 Overview
1.1 COVID-19 Drugs Product Introduction
1.2 Global COVID-19 Drugs 麻豆原创 Size Forecast
1.3 COVID-19 Drugs 麻豆原创 Trends & Drivers
1.3.1 COVID-19 Drugs Industry Trends
1.3.2 COVID-19 Drugs 麻豆原创 Drivers & Opportunity
1.3.3 COVID-19 Drugs 麻豆原创 Challenges
1.3.4 COVID-19 Drugs 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global COVID-19 Drugs Players Revenue Ranking (2023)
2.2 Global COVID-19 Drugs Revenue by Company (2019-2024)
2.3 Key Companies COVID-19 Drugs Manufacturing Base Distribution and Headquarters
2.4 Key Companies COVID-19 Drugs Product Offered
2.5 Key Companies Time to Begin Mass Production of COVID-19 Drugs
2.6 COVID-19 Drugs 麻豆原创 Competitive Analysis
2.6.1 COVID-19 Drugs 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by COVID-19 Drugs Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in COVID-19 Drugs as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Tablet
3.1.2 Injection
3.2 Global COVID-19 Drugs Sales Value by Type
3.2.1 Global COVID-19 Drugs Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global COVID-19 Drugs Sales Value, by Type (2019-2030)
3.2.3 Global COVID-19 Drugs Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Mild Symptom Patient
4.1.2 Critically Ill Patient
4.2 Global COVID-19 Drugs Sales Value by Application
4.2.1 Global COVID-19 Drugs Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global COVID-19 Drugs Sales Value, by Application (2019-2030)
4.2.3 Global COVID-19 Drugs Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global COVID-19 Drugs Sales Value by Region
5.1.1 Global COVID-19 Drugs Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global COVID-19 Drugs Sales Value by Region (2019-2024)
5.1.3 Global COVID-19 Drugs Sales Value by Region (2025-2030)
5.1.4 Global COVID-19 Drugs Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America COVID-19 Drugs Sales Value, 2019-2030
5.2.2 North America COVID-19 Drugs Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe COVID-19 Drugs Sales Value, 2019-2030
5.3.2 Europe COVID-19 Drugs Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific COVID-19 Drugs Sales Value, 2019-2030
5.4.2 Asia Pacific COVID-19 Drugs Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America COVID-19 Drugs Sales Value, 2019-2030
5.5.2 South America COVID-19 Drugs Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa COVID-19 Drugs Sales Value, 2019-2030
5.6.2 Middle East & Africa COVID-19 Drugs Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions COVID-19 Drugs Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions COVID-19 Drugs Sales Value
6.3 United States
6.3.1 United States COVID-19 Drugs Sales Value, 2019-2030
6.3.2 United States COVID-19 Drugs Sales Value by Type (%), 2023 VS 2030
6.3.3 United States COVID-19 Drugs Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe COVID-19 Drugs Sales Value, 2019-2030
6.4.2 Europe COVID-19 Drugs Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe COVID-19 Drugs Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China COVID-19 Drugs Sales Value, 2019-2030
6.5.2 China COVID-19 Drugs Sales Value by Type (%), 2023 VS 2030
6.5.3 China COVID-19 Drugs Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan COVID-19 Drugs Sales Value, 2019-2030
6.6.2 Japan COVID-19 Drugs Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan COVID-19 Drugs Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea COVID-19 Drugs Sales Value, 2019-2030
6.7.2 South Korea COVID-19 Drugs Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea COVID-19 Drugs Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia COVID-19 Drugs Sales Value, 2019-2030
6.8.2 Southeast Asia COVID-19 Drugs Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia COVID-19 Drugs Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India COVID-19 Drugs Sales Value, 2019-2030
6.9.2 India COVID-19 Drugs Sales Value by Type (%), 2023 VS 2030
6.9.3 India COVID-19 Drugs Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Sanofi
7.1.1 Sanofi Profile
7.1.2 Sanofi Main Business
7.1.3 Sanofi COVID-19 Drugs Products, Services and Solutions
7.1.4 Sanofi COVID-19 Drugs Revenue (US$ Million) & (2019-2024)
7.1.5 Sanofi Recent Developments
7.2 Novartis
7.2.1 Novartis Profile
7.2.2 Novartis Main Business
7.2.3 Novartis COVID-19 Drugs Products, Services and Solutions
7.2.4 Novartis COVID-19 Drugs Revenue (US$ Million) & (2019-2024)
7.2.5 Novartis Recent Developments
7.3 Shanghai Zhongxisanwei
7.3.1 Shanghai Zhongxisanwei Profile
7.3.2 Shanghai Zhongxisanwei Main Business
7.3.3 Shanghai Zhongxisanwei COVID-19 Drugs Products, Services and Solutions
7.3.4 Shanghai Zhongxisanwei COVID-19 Drugs Revenue (US$ Million) & (2019-2024)
7.3.5 Teva Recent Developments
7.4 Teva
7.4.1 Teva Profile
7.4.2 Teva Main Business
7.4.3 Teva COVID-19 Drugs Products, Services and Solutions
7.4.4 Teva COVID-19 Drugs Revenue (US$ Million) & (2019-2024)
7.4.5 Teva Recent Developments
7.5 Zydus Cadila
7.5.1 Zydus Cadila Profile
7.5.2 Zydus Cadila Main Business
7.5.3 Zydus Cadila COVID-19 Drugs Products, Services and Solutions
7.5.4 Zydus Cadila COVID-19 Drugs Revenue (US$ Million) & (2019-2024)
7.5.5 Zydus Cadila Recent Developments
7.6 Mylan
7.6.1 Mylan Profile
7.6.2 Mylan Main Business
7.6.3 Mylan COVID-19 Drugs Products, Services and Solutions
7.6.4 Mylan COVID-19 Drugs Revenue (US$ Million) & (2019-2024)
7.6.5 Mylan Recent Developments
7.7 Apotex
7.7.1 Apotex Profile
7.7.2 Apotex Main Business
7.7.3 Apotex COVID-19 Drugs Products, Services and Solutions
7.7.4 Apotex COVID-19 Drugs Revenue (US$ Million) & (2019-2024)
7.7.5 Apotex Recent Developments
7.8 Advanz Pharma
7.8.1 Advanz Pharma Profile
7.8.2 Advanz Pharma Main Business
7.8.3 Advanz Pharma COVID-19 Drugs Products, Services and Solutions
7.8.4 Advanz Pharma COVID-19 Drugs Revenue (US$ Million) & (2019-2024)
7.8.5 Advanz Pharma Recent Developments
7.9 Sun Pharma
7.9.1 Sun Pharma Profile
7.9.2 Sun Pharma Main Business
7.9.3 Sun Pharma COVID-19 Drugs Products, Services and Solutions
7.9.4 Sun Pharma COVID-19 Drugs Revenue (US$ Million) & (2019-2024)
7.9.5 Sun Pharma Recent Developments
7.10 Kyung Poong
7.10.1 Kyung Poong Profile
7.10.2 Kyung Poong Main Business
7.10.3 Kyung Poong COVID-19 Drugs Products, Services and Solutions
7.10.4 Kyung Poong COVID-19 Drugs Revenue (US$ Million) & (2019-2024)
7.10.5 Kyung Poong Recent Developments
7.11 Ipca Laboratories
7.11.1 Ipca Laboratories Profile
7.11.2 Ipca Laboratories Main Business
7.11.3 Ipca Laboratories COVID-19 Drugs Products, Services and Solutions
7.11.4 Ipca Laboratories COVID-19 Drugs Revenue (US$ Million) & (2019-2024)
7.11.5 Ipca Laboratories Recent Developments
7.12 Hanlim Pharmaceutical
7.12.1 Hanlim Pharmaceutical Profile
7.12.2 Hanlim Pharmaceutical Main Business
7.12.3 Hanlim Pharmaceutical COVID-19 Drugs Products, Services and Solutions
7.12.4 Hanlim Pharmaceutical COVID-19 Drugs Revenue (US$ Million) & (2019-2024)
7.12.5 Hanlim Pharmaceutical Recent Developments
7.13 Bristol Laboratories
7.13.1 Bristol Laboratories Profile
7.13.2 Bristol Laboratories Main Business
7.13.3 Bristol Laboratories COVID-19 Drugs Products, Services and Solutions
7.13.4 Bristol Laboratories COVID-19 Drugs Revenue (US$ Million) & (2019-2024)
7.13.5 Bristol Laboratories Recent Developments
7.14 Bayer
7.14.1 Bayer Profile
7.14.2 Bayer Main Business
7.14.3 Bayer COVID-19 Drugs Products, Services and Solutions
7.14.4 Bayer COVID-19 Drugs Revenue (US$ Million) & (2019-2024)
7.14.5 Bayer Recent Developments
7.15 Rising Pharmaceutical
7.15.1 Rising Pharmaceutical Profile
7.15.2 Rising Pharmaceutical Main Business
7.15.3 Rising Pharmaceutical COVID-19 Drugs Products, Services and Solutions
7.15.4 Rising Pharmaceutical COVID-19 Drugs Revenue (US$ Million) & (2019-2024)
7.15.5 Rising Pharmaceutical Recent Developments
7.16 Shanghai Pharma
7.16.1 Shanghai Pharma Profile
7.16.2 Shanghai Pharma Main Business
7.16.3 Shanghai Pharma COVID-19 Drugs Products, Services and Solutions
7.16.4 Shanghai Pharma COVID-19 Drugs Revenue (US$ Million) & (2019-2024)
7.16.5 Shanghai Pharma Recent Developments
7.17 Sichuan Sunny Hope
7.17.1 Sichuan Sunny Hope Profile
7.17.2 Sichuan Sunny Hope Main Business
7.17.3 Sichuan Sunny Hope COVID-19 Drugs Products, Services and Solutions
7.17.4 Sichuan Sunny Hope COVID-19 Drugs Revenue (US$ Million) & (2019-2024)
7.17.5 Sichuan Sunny Hope Recent Developments
7.18 Guangzhou Baiyunshan Guanghua Pharmaceutical
7.18.1 Guangzhou Baiyunshan Guanghua Pharmaceutical Profile
7.18.2 Guangzhou Baiyunshan Guanghua Pharmaceutical Main Business
7.18.3 Guangzhou Baiyunshan Guanghua Pharmaceutical COVID-19 Drugs Products, Services and Solutions
7.18.4 Guangzhou Baiyunshan Guanghua Pharmaceutical COVID-19 Drugs Revenue (US$ Million) & (2019-2024)
7.18.5 Guangzhou Baiyunshan Guanghua Pharmaceutical Recent Developments
7.19 CSPC Group
7.19.1 CSPC Group Profile
7.19.2 CSPC Group Main Business
7.19.3 CSPC Group COVID-19 Drugs Products, Services and Solutions
7.19.4 CSPC Group COVID-19 Drugs Revenue (US$ Million) & (2019-2024)
7.19.5 CSPC Group Recent Developments
7.20 KPC Group
7.20.1 KPC Group Profile
7.20.2 KPC Group Main Business
7.20.3 KPC Group COVID-19 Drugs Products, Services and Solutions
7.20.4 KPC Group COVID-19 Drugs Revenue (US$ Million) & (2019-2024)
7.20.5 KPC Group Recent Developments
7.21 Jinghua Pharmaceutical Group
7.21.1 Jinghua Pharmaceutical Group Profile
7.21.2 Jinghua Pharmaceutical Group Main Business
7.21.3 Jinghua Pharmaceutical Group COVID-19 Drugs Products, Services and Solutions
7.21.4 Jinghua Pharmaceutical Group COVID-19 Drugs Revenue (US$ Million) & (2019-2024)
7.21.5 Jinghua Pharmaceutical Group Recent Developments
7.22 Zhongsheng Pharma
7.22.1 Zhongsheng Pharma Profile
7.22.2 Zhongsheng Pharma Main Business
7.22.3 Zhongsheng Pharma COVID-19 Drugs Products, Services and Solutions
7.22.4 Zhongsheng Pharma COVID-19 Drugs Revenue (US$ Million) & (2019-2024)
7.22.5 Zhongsheng Pharma Recent Developments
7.23 North China Pharmaceutical Group
7.23.1 North China Pharmaceutical Group Profile
7.23.2 North China Pharmaceutical Group Main Business
7.23.3 North China Pharmaceutical Group COVID-19 Drugs Products, Services and Solutions
7.23.4 North China Pharmaceutical Group COVID-19 Drugs Revenue (US$ Million) & (2019-2024)
7.23.5 North China Pharmaceutical Group Recent Developments
8 Industry Chain Analysis
8.1 COVID-19 Drugs Industrial Chain
8.2 COVID-19 Drugs Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 COVID-19 Drugs Sales Model
8.5.2 Sales Channel
8.5.3 COVID-19 Drugs Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
Sanofi
Novartis
Shanghai Zhongxisanwei
Teva
Zydus Cadila
Mylan
Apotex
Advanz Pharma
Sun Pharma
Kyung Poong
Ipca Laboratories
Hanlim Pharmaceutical
Bristol Laboratories
Bayer
Rising Pharmaceutical
Shanghai Pharma
Sichuan Sunny Hope
Guangzhou Baiyunshan Guanghua Pharmaceutical
CSPC Group
KPC Group
Jinghua Pharmaceutical Group
Zhongsheng Pharma
North China Pharmaceutical Group
听
听
*If Applicable.
